Conference Coverage
Conference Coverage
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL
ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.
Conference Coverage
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL
The use of a nurse navigation program to facilitate care helped iron out racial disparities that could lead to poor outcomes.
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
Conference Coverage
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
Decoding biosimilar approvals
SAN FRANCISCO – Regulators must consider several factors when expanding the use of an approved biosimilar from one indication to another, based on...
Conference Coverage
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...